Iovance Biotherapeutics Announces First Patient Dosed in Cohort 4 of Pivotal InnovaTIL-01 Study of Lifileucel in Metastatic Melanoma

Source: West, May 2019

– Patient dosing commenced in pivotal metastatic melanoma cohort –

– Submission for regulatory approval of lifileucel is on target for late 2020 –

SAN CARLOS, Calif., April 02, 2019 (GLOBE NEWSWIRE) — Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that first patient has been dosed in Cohort 4, the pivotal cohort of the innovaTIL-01 (C-144-01) study of lifileucel. Cohort 4 is designed to enroll 75 patients with advanced melanoma.

read the original full article